Latest | F'cast | |
---|---|---|
Div Yield | 3.0% | |
Div Cover | 0.0 | |
Op Mrgn | 3.1% | |
ROCE | 5.6% |
Latest | F'cast | |
---|---|---|
P/E | 696.0 | |
PEG | n/a | |
Pr/Revenue | 4.1 | |
Pr/Book | 6.6 |
Latest | F'cast | |
---|---|---|
Revenue | 1.4% | |
PBT | -88.5% | |
EPS | -97.6% | |
DPS | 5.7% |
Year Ending | Revenue ($m) | Pre-tax ($m) | EPS | P/E | PEG | EPS Grth. | Div | Yield |
---|---|---|---|---|---|---|---|---|
31-Dec-19 | 46,840.00 | 11,464.00 | 384.00¢ | 23.7 | 0.4 | +64% | 226.00¢ | 2.5% |
31-Dec-20 | 47,994.00 | 8,791.00 | 179.00¢ | 45.7 | n/a | -53% | 248.00¢ | 3.0% |
31-Dec-21 | 48,704.00 | 13,879.00 | 488.00¢ | 15.7 | 0.1 | +173% | 264.00¢ | 3.4% |
31-Dec-22 | 59,283.00 | 16,444.00 | 573.00¢ | 19.4 | 1.1 | +17% | 280.00¢ | 2.5% |
31-Dec-23 | 60,115.00 | 1,889.00 | 14.00¢ | 778.7 | n/a | -98% | 296.00¢ | 2.7% |
Year Ending | Revenue ($m) | Pre-tax ($m) | EPS | P/E | PEG | EPS Grth. | Div | Yield |
---|---|---|---|---|---|---|---|---|
31-Dec-24 | 64,006.76 | 23,799.60 | 775.71¢ | 12.6 | 0.0 | +5,441% | 301.75¢ | 0.0% |
31-Dec-25 | 67,071.07 | 28,236.72 | 939.31¢ | 10.4 | 0.5 | +21% | 315.17¢ | 0.0% |
31-Dec-26 | 71,276.72 | 31,187.77 | 1,060.17¢ | 9.2 | 0.7 | +13% | 329.70¢ | 0.0% |
Copyright © 2024 FactSet Research Systems Inc. All rights reserved.
Merck tops Q3 earnings forecasts despite slower ... | 31-Oct-2024 | ShareCast |
Merck to buy drug targeting B-cell diseases for ... | 09-Aug-2024 | ShareCast |
Merck to buy EyeBio for up to $3bn | 29-May-2024 | ShareCast |
Currency | US Dollars |
Share Price | $ 98.56 |
Change Today | $ 1.12 |
% Change | 1.15 % |
52 Week High | $132.96 |
52 Week Low | $96.31 |
Volume | 3,911,626 |
Shares Issued | 2,531.63m |
Market Cap | $249,530m |
Beta | 0.19 |
RiskGrade | 92 |
Strong Buy | 10 |
Buy | 11 |
Neutral | 4 |
Sell | 0 |
Strong Sell | 0 |
Total | 25 |
Time | Volume / Share Price |
11:50 | 1,000 @ $98.56 |
11:50 | 100 @ $98.57 |
11:50 | 2,495 @ $98.58 |
11:50 | 301 @ $98.59 |
11:50 | 100 @ $98.58 |
You are here: research